Business ❯ Healthcare ❯ Pharmaceuticals

Drug Development

Clinical Trials GLP-1 Drugs Weight Loss Drugs Acquisitions Oncology Eli Lilly Obesity Drugs Eli Lilly and Company Cancer Treatment Obesity Treatments

PolyPid Nears Completion of Rolling FDA Filing for D‑PLEX100

Fast‑track status could shorten review to speed the infection‑prevention drug toward hospitals.

Merck KGaA Raises 2026 Profit Outlook After Q1 Beat

Novo Nordisk Lifts 2026 Outlook as Wegovy Pill Powers Big Q1 Beat

Analysts Lift Eli Lilly Targets After Blowout Quarter and Foundayo Debut

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion to Bolster Eye Pipeline

ADC Therapeutics Reports Higher Q1 Sales and Lower Costs as Zenlonta Readouts Near

Merck Reports Q1 Loss From Cidara Charge as Sales Beat and 2026 Outlook Rises

AstraZeneca Tops Q1 Forecasts, Reaffirms 2026 Outlook as Oncology Fuels Growth

AbbVie Tops Q1 and Raises 2026 Outlook as Skyrizi and Rinvoq Offset Humira Decline

Sun Pharma Said to Make $13 Billion All-Cash Offer for Organon

Cramer Touts Intel Comeback Under Lip‑Bu Tan as Earnings Loom

Novo Nordisk Partners With OpenAI to Speed Drug Development and Operations

Boehringer Ingelheim Transfers CT-155 Commercial Rights to Click Therapeutics With $50 Million Backing

Bank of America Cuts Hims & Hers Target as GLP‑1 Pivot Squeezes Margins

Neurocrine to Acquire Soleno for $2.9 Billion in All-Cash Tender

EPO Signals Patent Grant for Silo Pharma’s PTSD Prevention Approach

Fosun Reports 2025 Results With RMB23.4 Billion in Write-Downs and a Higher 2026 Payout Target

Bristol Gate’s Q4 Letter Reaffirms Dividend-Growth Focus as Market Breadth Improves

Merck to Acquire Terns for $6.7 Billion to Add Promising Leukemia Drug

Sanofi Licenses Kali’s Tri-Specific Autoimmune Antibody KT501 in Deal Worth Up to $1.23 Billion